-
Oxforb BioTherapeutics expands its strategic collaboration with WuXi Biologics
pharmafocusasia
December 12, 2018
WuXi Biologics (2269.HK), a leading global open source biological technology platform company offering integrated solutions for discovery, development and biological ....
-
WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity
en-cphi.cn
December 12, 2018
WuXi Biologics announced that it has achieved a breakthrough in cell culture productivity for an Fc-fusion protein.
-
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
expressbpd
December 11, 2018
WuXi Biologics and Oxford BioTherapeutics Ltd. announced the expansion of their strategic and innovative immuno-oncology (IO) alliance...
-
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
en-cphi.cn
December 10, 2018
WuXi Biologics announces a strategic collaboration with Brii Biosciences.
-
WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market"
en-cphi.cn
December 07, 2018
This award recognizes the rapid growth, significant accomplishments, and growing global influence achieved by WuXi Biologics in 2018.
-
WuXi Biologics Selected as Forbes Asia’s Best Under A Billion 2018
en-cphi.cn
November 30, 2018
WuXi Biologics announced that it has been selected as Forbes Asia’s Best Under A Billion 2018.
-
WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai
en-cphi.cn
November 22, 2018
WuXi Biologics today announced that construction of a global innovation center has commenced in the district of Fengxian in Shanghai.
-
WuXi Biologics’ Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting
en-cphi.cn
November 08, 2018
WuXi Biologics announced Chief Executive Officer of WuXi Biologics, has been appointed by International Society for Pharmaceutical Engineering (ISPE) to serve on the International Board of Directors for a two-year term. Dr. Chris Chen is also the first Bo
-
WuXi Biologics Commenced Construction of 48,000L Biologics Commercial Manufacturing Center in Shijiazhuang
en-cphi.cn
November 01, 2018
The new Biologics Center will be one of the largest in northern China
-
CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics
en-cphi.cn
October 24, 2018
CANbridge Plans to Submit First Rare Disease IND in China in 2019
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight June 2024: Globalization on the Go
